See more : ENDI Corp. (ENDI) Income Statement Analysis – Financial Results
Complete financial analysis of DIAGNOS Inc. (DGNOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DIAGNOS Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Ras Resorts and Apart Hotels Limited (RASRESOR.BO) Income Statement Analysis – Financial Results
- Generation Hemp, Inc. (GENH) Income Statement Analysis – Financial Results
- Wheels India Limited (WHEELS.NS) Income Statement Analysis – Financial Results
- Country Garden Holdings Company Limited (2007.HK) Income Statement Analysis – Financial Results
- Canaccord Genuity Group Inc. (CF.TO) Income Statement Analysis – Financial Results
DIAGNOS Inc. (DGNOF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.diagnos.ca
About DIAGNOS Inc.
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K | 326.47K | 1.61M | 2.39M | 981.48K | 564.18K | 2.70M | 1.51M | 1.33M | 1.07M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
Cost of Revenue | 1.01M | 857.13K | 614.60K | 804.97K | 1.09M | 1.09M | 1.32M | 1.67M | 1.18M | 1.11M | 2.24M | 1.02M | 104.54K | 24.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -837.94K | -418.30K | -347.53K | -473.46K | -759.37K | -759.37K | 290.90K | 719.10K | -203.51K | -541.43K | 464.53K | 490.00K | 1.22M | 1.05M | 358.07K | 1.89M | 1.86M | 775.72K | 709.19K | 111.75K | 387.72K | 128.62K | 7.00K |
Gross Profit Ratio | -492.45% | -95.32% | -130.13% | -142.81% | -232.60% | -232.60% | 18.04% | 30.09% | -20.73% | -95.97% | 17.17% | 32.47% | 92.13% | 97.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 1.08M | 603.35K | 0.00 | 0.00 | 0.00 | 922.49K | 0.00 | 1.18M | 1.07M | 1.31M | 1.00M | 831.56K | 793.96K | 614.13K | 618.21K | 674.24K | 193.82K | 101.25K | 179.58K | 784.10K | -4.56K | 192.92K | 1.44M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.84M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -293.72K | -295.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 1.77M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 2.46M | 2.10M | 1.69M | 3.23M | 2.02M | 1.39M | 1.09M | 1.10M | 426.23K | 567.04K | 1.45M |
Other Expenses | 0.00 | 100.14K | 264.28K | 85.80K | 52.31K | 52.31K | 0.00 | 0.00 | 1.07M | 0.00 | 0.00 | -374.80K | -240.63K | -204.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 1.76M | 2.24M | 1.94M | 2.32M | 2.17M | 2.17M | 2.76M | 2.69M | 2.52M | 2.13M | 2.11M | 2.55M | 3.15M | 2.66M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
Cost & Expenses | 3.86M | 3.10M | 2.55M | 3.13M | 3.26M | 3.26M | 4.08M | 4.36M | 3.70M | 3.23M | 4.35M | 3.56M | 3.25M | 2.69M | 2.28M | 4.04M | 2.29M | 1.52M | 1.30M | 1.91M | 496.73K | 899.32K | 3.06M |
Interest Income | 6.89K | 5.38K | 5.38K | 3.23K | 3.23K | 1.48K | 0.00 | 0.00 | 0.00 | 0.00 | 5.23K | 11.89K | 27.01K | 8.79K | 15.44K | 76.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 550.17K | 53.78K | 32.16K | 347.11K | 1.03M | 1.03M | 827.77K | 955.38K | 469.22K | 159.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.25K | 0.00 | 0.00 |
Depreciation & Amortization | 124.21K | 101.17K | 105.80K | 92.84K | 101.72K | 191.32K | 230.19K | 192.65K | 82.37K | 43.71K | 62.19K | 89.52K | 81.36K | 125.94K | 186.17K | 188.36K | 79.67K | 32.68K | 29.28K | 23.66K | 75.05K | 139.36K | 176.19K |
EBITDA | -2.45M | -2.10M | -2.45M | -2.61M | -2.69M | -2.69M | -2.66M | -1.78M | -2.64M | -2.62M | -1.58M | -1.97M | -1.84M | -1.49M | -1.74M | -1.97M | -347.40K | -711.98K | -560.21K | -1.77M | -33.96K | -631.34K | -2.88M |
EBITDA Ratio | -1,437.61% | -557.99% | -723.29% | -785.96% | -822.85% | -822.39% | -164.64% | -74.54% | -269.07% | -465.19% | -58.55% | -130.30% | -134.65% | -184.81% | -485.96% | -104.35% | -18.65% | -91.78% | -78.99% | -1,587.96% | -8.76% | -490.86% | -41,123.96% |
Operating Income | -3.69M | -2.55M | -2.02M | -2.71M | -2.88M | -2.88M | -2.89M | -1.97M | -2.72M | -2.67M | -1.65M | -2.06M | -2.22M | -1.58M | -1.93M | -2.16M | -427.07K | -744.66K | -589.49K | -1.80M | -109.01K | -770.70K | -3.05M |
Operating Income Ratio | -2,168.30% | -582.10% | -756.03% | -816.65% | -881.45% | -881.00% | -178.91% | -82.60% | -277.46% | -472.94% | -60.85% | -136.23% | -167.19% | -147.33% | -537.96% | -114.34% | -22.92% | -96.00% | -83.12% | -1,609.13% | -28.12% | -599.21% | -43,640.96% |
Total Other Income/Expenses | 568.95K | -259.14K | 608.66K | 232.12K | -505.21K | -1.03M | -622.77K | 232.83K | 475.50K | -159.40K | 5.23K | 11.89K | 27.01K | 275.63K | 0.00 | 0.00 | 0.00 | 124.41K | 8.37K | 64.85K | 26.20K | -57.70K | -123.17K |
Income Before Tax | -3.12M | -2.61M | -2.05M | -3.38M | -3.90M | -3.90M | -3.09M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | 0.00 | 0.00 | 0.00 | -620.25K | -581.12K | -1.73M | -82.81K | -828.40K | -3.18M |
Income Before Tax Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,195.74% | -1,195.74% | -191.55% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | 0.00% | 0.00% | 0.00% | -79.96% | -81.94% | -1,551.10% | -21.36% | -644.07% | -45,400.57% |
Income Tax Expense | 0.00 | 153.92K | 296.44K | 432.91K | -64.67K | -64.67K | -192.19K | -1.32M | 0.00 | 0.00 | 0.00 | -540.22K | 28.02K | -508.81K | -15.44K | -76.43K | -28.99K | -3.12K | 747.00 | 12.79K | 47.25K | -33.48K | 4.58K |
Net Income | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M | -3.84M | -2.90M | -2.93M | -3.19M | -2.83M | -1.64M | -2.04M | -2.19M | -1.31M | -1.91M | -2.08M | -398.09K | -617.13K | -581.86K | -1.75M | -130.06K | -762.98K | -3.18M |
Net Income Ratio | -1,833.93% | -594.35% | -768.07% | -1,020.42% | -1,175.93% | -1,175.93% | -179.63% | -122.57% | -325.27% | -501.19% | -60.66% | -135.44% | -165.16% | -121.68% | -533.64% | -110.28% | -21.37% | -79.56% | -82.05% | -1,562.55% | -33.54% | -593.21% | -45,465.96% |
EPS | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
EPS Diluted | -0.04 | -0.04 | -0.03 | -0.05 | -0.09 | -0.20 | -0.17 | -0.24 | -0.30 | -0.29 | -0.21 | -0.31 | -0.35 | -0.25 | -0.40 | -0.46 | -0.10 | -0.17 | -0.18 | -0.65 | -0.09 | -0.71 | -1.06 |
Weighted Avg Shares Out | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
Weighted Avg Shares Out (Dil) | 72.82M | 69.62M | 68.73M | 63.11M | 40.74M | 18.84M | 16.89M | 12.37M | 10.62M | 9.85M | 7.78M | 6.58M | 6.20M | 5.23M | 4.80M | 4.56M | 4.07M | 3.62M | 3.15M | 2.68M | 1.41M | 1.07M | 3.00M |
DIAGNOS Announces Closing of First Tranche of Private Placement
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
DIAGNOS Announces Grant of Stock Options
DIAGNOS Announces Grant of Stock Options
DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
DIAGNOS Announces Closing of Second and Final Tranche of
DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
DIAGNOS Announces Grant of Stock Options
Source: https://incomestatements.info
Category: Stock Reports